{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:30:43Z","timestamp":1762867843123,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.oret.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T19:33:32Z","timestamp":1562355212000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Value of Prior Response to Anti\u2013Vascular Endothelial Growth Factor for Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"4","author":[{"given":"Rahul N.","family":"Khurana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis K.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren F.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avanti","family":"Ghanekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivaylo","family":"Stoilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"Lucentis [prescribing information]","key":"10.1016\/j.oret.2019.06.008_bib1"},{"year":"2018","series-title":"Eylea [prescribing information]","key":"10.1016\/j.oret.2019.06.008_bib2"},{"key":"10.1016\/j.oret.2019.06.008_bib3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.06.008_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.008_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.06.008_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.008_bib7","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"year":"2015","series-title":"2015 global trends in retina","key":"10.1016\/j.oret.2019.06.008_bib8"},{"key":"10.1016\/j.oret.2019.06.008_bib9","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","article-title":"Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study","volume":"122","author":"Kuroda","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.008_bib10","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/bjophthalmol-2015-308077","article-title":"UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections","volume":"100","author":"Madhusudhana","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2019.06.008_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","article-title":"Moving to a world beyond \u201cp\u2009<\u20090.05\u201d","volume":"73","author":"Wasserstein","year":"2019","journal-title":"Am Stat"},{"key":"10.1016\/j.oret.2019.06.008_bib12","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","article-title":"Scheduled versus pro re nata dosing in the VIEW trials","volume":"122","author":"Richard","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.008_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin study treat-and-extend protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.008_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","article-title":"Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration","volume":"122","author":"Peden","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.008_bib15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajo.2014.05.025","article-title":"Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration","volume":"158","author":"Fauser","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.06.008_bib16","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1136\/bjophthalmol-2015-306771","article-title":"A\u00a0model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab","volume":"99","author":"Saunders","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2019.06.008_bib17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/eye.2016.97","article-title":"Variability of disease activity in patients treated with ranibizumab for neovascular age-related macular degeneration","volume":"30","author":"Enders","year":"2016","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019304373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019304373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:27:50Z","timestamp":1762853270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653019304373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2468653019304373"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2019.06.008","relation":{},"ISSN":["2468-6530"],"issn-type":[{"type":"print","value":"2468-6530"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Value of Prior Response to Anti\u2013Vascular Endothelial Growth Factor for Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license ?(<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/?creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}